Dr. Curis joined the ECHO research team in October 2024. He attended the University of Rhode Island for his undergraduate bachelor’s degree in Biological and Health Sciences. He then attended Avalon University School of Medicine for his medical doctorate. He […]
Read more »Research is a core focus at Eastern Connecticut Hematology & Oncology (ECHO). For over 35 years, we have excelled at bringing the latest advancements and treatments to patients across Eastern Connecticut. This includes offering our patients the possibility to participate in promising […]
Read more »Beigene’s CELESTIAL Trial This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia. The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination of venetoclax with obinutuzumab. Some patients […]
Read more »The Beigene’s CELESTIAL clinical trial for chronic lymphocytic leukemia This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia. The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination […]
Read more »Below is information on the INTerpath 009 study which is a clinical trial for early-stage non-small cell lung cancer (NSCLC). This clinical trial is trying to determine if an investigational study drug combination, when given after initial treatment and surgery, […]
Read more »A Phase 3 randomized double-blind study of adjuvant pembrolizumab with or without V940 in participants with resectable Stage II to IIIB (N 2) non-small cell lung cancer who are not achieving pCR after receiving neoadjuvant pembolizumab with platinum-based doublet chemotherapy […]
Read more »Chronic Lymphocytic Leukemia (CLL) is a cancer that affects the blood and bone marrow, specifically the white blood cells called lymphocytes. CLL is a chronic leukemia, meaning it develops slowly and can progress slowly over months or years. It is one of the […]
Read more »The ECHO Research Department recently hosted Valerie Gabarre, MD (Medical Director) and Berangere Vasseu, MD (Chief Medical Officer) from the French company OSE Immunotherapeutics. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for […]
Read more »We are thrilled to announced that ECHO has enrolled the first patient in the world into a new clinical trial. The trial is for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed while receiving maintenance immunotherapy. The trial will compare […]
Read more »ECHO is proud to have a leading edge research team who provides patients with access to some of the most current clinical trials in the world. One of these trials is for unresectable locally advanced or metastatic colon cancer with […]
Read more »
